218 patents
Page 4 of 11
Utility
Salts of an LSD1 inhibitor
15 Nov 22
The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou
Filed: 12 Jun 20
Utility
Tricyclic heterocycles as BET protein inhibitors
15 Nov 22
Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
Filed: 11 Dec 20
Utility
Indazole compounds and uses thereof
8 Nov 22
Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
Filed: 21 Jul 20
Utility
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
18 Oct 22
The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 4 Mar 20
Utility
Crystalline forms of a FGFR inhibitor and processes for preparing the same
18 Oct 22
The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
Filed: 6 Feb 20
Utility
Heterocyclic compounds as immunomodulators
11 Oct 22
Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
Filed: 26 Jun 20
Utility
Solid forms of an FGFR inhibitor and processes for preparing the same
11 Oct 22
The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Timothy C. Burn
Filed: 3 May 19
Utility
Imidazopyridazine and imidazopyridine compounds and uses thereof
4 Oct 22
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 19 Dec 19
Utility
Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
27 Sep 22
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
Filed: 8 Sep 20
Utility
Tricyclic amine compounds as CDK2 inhibitors
20 Sep 22
Qinda Ye, Ken Mukai, Liangxing Wu, Wenqing Yao
Filed: 30 Apr 20
Utility
Tricyclic amine compounds as CDK2 inhibitors
13 Sep 22
The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Neil Lajkiewicz, Ken Mukai, Liangxing Wu, Wenqing Yao
Filed: 30 Apr 20
Utility
Heterocyclylamines as PI3K inhibitors
6 Sep 22
Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
Filed: 24 Mar 20
Utility
Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
30 Aug 22
The present application provides imidazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Qinda Ye, Jingwei Li, Ken Mukai, Brandon Smith, Liangxing Wu, Wenqing Yao, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 13 Aug 20
Utility
Imidazopyridazine and imidazopyridine compounds and uses thereof
30 Aug 22
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 19 Dec 19
Utility
Heteroaryl amide compounds as sting activators
30 Aug 22
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
Filed: 23 Oct 20
Utility
Heterocyclic compounds as immunomodulators
16 Aug 22
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 29 Dec 20
Utility
Pyrazolopyridine compounds and uses thereof
9 Aug 22
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Alexander Sokolsky, Oleg Vechorkin, Kai Liu, Jun Pan, Wenqing Yao, Qinda Ye
Filed: 22 Jul 19
Utility
JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
9 Aug 22
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
Richard L. Schaub, Kevin O'Hayer
Filed: 5 Mar 20
Utility
Heterocyclic compounds as immunomodulators
9 Aug 22
Liangxing Wu, Bo Shen, Jingwei Li, Zhenwu Li, Kai Liu, Fenglei Zhang, Wenqing Yao
Filed: 11 Dec 20
Utility
Derivatives of an FGFR inhibitor
9 Aug 22
The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.
Ming Tao, Jason Boer
Filed: 3 Dec 20